ArticleJournal of translational medicine2026
Naringin promotes angiogenesis in bone fracture healing via TAS2R39-Ca
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundBone fracture, a widespread bone defect disease, is often caused by mechanical forces and requires long-term healing. Angiogenesis is essential for the repair of various bone defects, with the transport function of blood vessels serving as a key determinant of successful osteogenic regeneration. This study aimed to clarify the angiogenic effects of naringin and investigate the molecular mechanism. We constructed TAS2R39‑deficient HUVECs and established a young mouse tibial fracture model to explore how naringin activates TAS2R39 to promote angiogenesis.
methodsImmunofluorescence staining, western blot and RT-qPCR were performed to detect the expression of TAS2R39 and autophagy. Wound healing assay, tube formation assay, western blot and RT-qPCR were performed to detect angiogenesis of HUVECs. mRNA-seq was performed to explored potential mechanism. Flow cytometry, immunofluorescence staining and western blot were employed to analysis Ca2 + signaling. Micro-CT and immunofluorescence staining were used to detect angiogenesis and osteogenesis of naringin in vivo.
resultsWe confirmed angiogenic effect of naringin and observed TAS2R39 activation in naringin-treated HUVECs. Through TAS2R39 knocked-down and inhibitors, we observed and confirmed that naringin activated TAS2R39 and decreased intercellular Ca²⁺ elevation thereby promoting cellular autophagy and ultimately enhancing the angiogenesis of HUVECs.
conclusionNaringin promotes angiogenesis by upregulating TAS2R39, lowering intracellular Ca²⁺, and enhancing autophagy. This TAS2R39-Ca²⁺-autophagy axis represents a novel mechanism for fracture repair in young individuals.
Indexed as
Identifiers
42449359What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.